Rheumatoid Arthritis
Conditions
Keywords
Musculoskeletal Disease, Arthritis, Joint Diseases, anti-inflammatory agents, antirheumatic agents
Brief summary
The primary objective of the study was to compare the safety and efficacy of multiple doses of upadacitinib versus placebo in adults with moderately to severely active rheumatoid arthritis (RA) on stable background methotrexate therapy who had not shown an adequate response to methotrexate alone.
Interventions
DRUGPlacebo
Tablets for oral administration
DRUGUpadacitinib
Tablets for oral administration
Sponsors
AbbVie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosed with RA based on either the 1987-revised American College of Rheumatology (ACR) classification criteria or the 2010 ACR/European League against Rheumatism (EULAR) criteria for ≥ 3 months. 2. Have active RA as defined by the following minimum disease activity criteria: * ≥ 6 swollen joints (based on 66 joint counts) at Screening and Baseline Visits. * ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits. * high-sensitivity C-reactive protein (hsCRP) \> upper limit of normal (ULN) OR positive for both rheumatoid factor and anti-cyclic citrullinated peptide (CCP) at Screening. 3. Subjects must have been receiving oral or parenteral methotrexate therapy ≥ 3 months and on a stable prescription of 7.5 to 25 mg/week for at least 4 weeks prior to Baseline Visit. Subjects should also be on a stable dose of folic acid (or equivalent) for at least 4 weeks prior to Baseline Visit. Subjects should continue with their stable doses of methotrexate and folic acid throughout the study. 4. Except for MTX, subjects must have discontinued all oral disease-modifying anti-rheumatic drugs (DMARDs) prior to Baseline Visit as specified below or for at least five times the mean terminal elimination half-life of a drug, whichever is longer: * ≥ 4 weeks prior to Baseline Visit for minocycline, penicillamine, sulfasalazine, hydroxychloroquine, chloroquine, azathioprine, gold formulations, cyclophosphamide * ≥ 8 weeks prior to Baseline Visit for leflunomide if no elimination procedure was followed, or adhere to a washout procedure (i.e., 11 days washout with colestyramine, or 30 days washout with activated charcoal) 5. Subject has a negative tuberculosis (TB) Screening Assessment. If the subject has evidence of a latent TB infection, the subject must initiate and complete a minimum of 2 weeks (or per local guidelines, whichever is longer) of an ongoing TB prophylaxis or have documented completion of a full course of TB prophylaxis, prior to Baseline Visit. 6. Subjects can be taking non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen, oral corticosteroids (equivalent to prednisone ≤ 10 mg), or inhaled corticosteroids at a stable dose for at least 4 weeks prior to Baseline Visit for stable medical conditions and should be kept at a stable dose throughout the study. NSAIDs, acetaminophen, tramadol, codeine, hydrocodone and propoxyphene taken as needed are allowed but may not be taken 24 hours prior to any study visit. Oral and inhaled corticosteroids taken as needed are allowed but may not be taken 24 hours prior to any study visit. 7. Subjects must have discontinued high potency opiates including (but not limited to): oxycodone, oxymorphone, fentanyl, levorphanol, buprenorphine, methadone, hydromorphone, and morphine at least 4 weeks prior to Baseline Visit.
Exclusion criteria
1. Female who is pregnant or breastfeeding. 2. Prior exposure to Janus activated kinase (JAK) inhibitor (e.g., tofacitinib, baricitinib). 3. Prior exposure to any investigational or approved biologic RA therapy. 4. Receipt of any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives of the drug (whichever is longer) prior to Week 0 Visit. 5. Current or expected need of other immunosuppressant medications, except methotrexate. Use of oral intake of \> 10 mg prednisone/day or equivalent corticosteroid therapy (see inclusion criterion 7). 6. Subject has been treated with intra-articular or parenteral administration of corticosteroids in the preceding 8 weeks prior to the Week 0 Visit. 7. Screening laboratory values meeting the following criteria: * Serum aspartate transaminase (AST) or alanine transaminase (ALT) \> 1.5 × ULN * Estimated glomerular filtration rate (eGRF) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula \< 40 mL/min/1.73 m² * Total white blood cell count (WBC) \< 3,000/µL * Absolute neutrophil count (ANC) \< 1,200/µL * Platelet count \< 100,000/µL * Absolute lymphocytes count \< 750/ µL * Hemoglobin \< 9 gm/dL
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Baseline and Week 12 | Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | Baseline and Week 12 | A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP). |
| Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 | Week 12 | The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale (VAS) from 0 to 100 mm). DAS28(CRP) scores range from 0 to approximately 10 where higher scores indicate more disease activity. LDA is defined as a DAS28(CRP) score \< 3.2. |
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | Baseline and Week 12 | A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 50% improvement in 68-tender joint count; * ≥ 50% improvement in 66-swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician's global assessment of disease activity * Patient's global assessment of disease activity * Patient's assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP). |
| Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12 | Week 12 | The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA is defined as a CDAI score ≤ 10. |
| Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12 | Week 12 | The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. CR is defined as a CDAI score ≤ 2.8. |
| Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 | Week 12 | The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale from 0 to 100 mm). DAS28(CRP) scores range from 0 to 10 where higher scores indicate more disease activity. CR is defined as a DAS28(CRP) score \< 2.6. |
Countries
Bulgaria, Chile, Czechia, Hungary, Israel, Latvia, Mexico, Poland, Puerto Rico, Russia, Slovakia, South Africa, Spain, Turkey (Türkiye), Ukraine, United States
Participant flow
Recruitment details
A total of 300 adults with rheumatoid arthritis (RA) were enrolled at 59 study sites located in 16 countries.
Pre-assignment details
Eligible participants were randomly assigned in a 1:1:1:1:1:1 ratio to receive 1 of 5 doses of upadacitinib or placebo for 12 weeks. Participants who completed the 12-week treatment period completed a 30-day follow-up visit or had the option to enter an open-label extension study M13-538 (NCT02049138).
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received placebo capsules twice daily for 12 weeks. | 50 |
| Upadacitinib 3 mg BID Participants received 3 mg upadacitinib twice daily (BID) for 12 weeks. | 50 |
| Upadacitinib 6 mg BID Participants received 6 mg upadacitinib twice daily (BID) for 12 weeks. | 50 |
| Upadacitinib 12 mg BID Participants received 12 mg upadacitinib twice daily (BID) for 12 weeks. | 50 |
| Upadacitinib 18 mg BID Participants received 18 mg upadacitinib twice daily (BID) for 12 weeks. | 50 |
| Upadacitinib 24 mg QD Participants received 24 mg upadacitinib once daily (QD) for 12 weeks. | 49 |
| Total | 299 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 1 | 1 | 1 | 5 | 1 |
| Overall Study | Lost to Follow-up | 0 | 0 | 0 | 1 | 1 | 1 |
| Overall Study | Randomized in Error | 0 | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 4 | 0 | 5 | 1 | 1 | 2 |
Baseline characteristics
| Characteristic | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 54.5 years STANDARD_DEVIATION 11.51 | 53.1 years STANDARD_DEVIATION 12.15 | 54.8 years STANDARD_DEVIATION 12.47 | 55.7 years STANDARD_DEVIATION 11.65 | 54.6 years STANDARD_DEVIATION 13.65 | 56.2 years STANDARD_DEVIATION 11.79 | 54.8 years STANDARD_DEVIATION 12.16 |
| Age, Customized 18 to < 45 years | 9 Participants | 11 Participants | 9 Participants | 7 Participants | 13 Participants | 7 Participants | 56 Participants |
| Age, Customized 45 to < 65 years | 32 Participants | 30 Participants | 30 Participants | 32 Participants | 25 Participants | 27 Participants | 176 Participants |
| Age, Customized ≤ 65 years | 9 Participants | 9 Participants | 11 Participants | 11 Participants | 12 Participants | 15 Participants | 67 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 11 Participants | 8 Participants | 17 Participants | 17 Participants | 7 Participants | 8 Participants | 68 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 39 Participants | 42 Participants | 33 Participants | 33 Participants | 43 Participants | 41 Participants | 231 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Black or African American | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Multi-race | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 50 Participants | 48 Participants | 49 Participants | 48 Participants | 49 Participants | 49 Participants | 293 Participants |
| Sex: Female, Male Female | 38 Participants | 40 Participants | 34 Participants | 41 Participants | 42 Participants | 42 Participants | 237 Participants |
| Sex: Female, Male Male | 12 Participants | 10 Participants | 16 Participants | 9 Participants | 8 Participants | 7 Participants | 62 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 50 | 0 / 50 | 0 / 50 | 0 / 50 | 0 / 50 | 0 / 49 |
| other Total, other adverse events | 2 / 50 | 5 / 50 | 7 / 50 | 17 / 50 | 6 / 50 | 6 / 49 |
| serious Total, serious adverse events | 0 / 50 | 0 / 50 | 2 / 50 | 1 / 50 | 3 / 50 | 2 / 49 |
Outcome results
Primary
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Population: All randomized participants who received at least 1 dose of study drug; last observation carried forward (LOCF) imputation was used for participants with missing data at Week 12 if prior post-baseline data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 50.0 percentage of participants |
| Upadacitinib 3 mg BID | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 64.6 percentage of participants |
| Upadacitinib 6 mg BID | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 73.5 percentage of participants |
| Upadacitinib 12 mg BID | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 81.6 percentage of participants |
| Upadacitinib 18 mg BID | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 76.6 percentage of participants |
| Upadacitinib 24 mg QD | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 81.6 percentage of participants |
p-value: 0.153Chi-squared
p-value: 0.018Chi-squared
p-value: 0.001Chi-squared
p-value: 0.008Chi-squared
p-value: 0.001Chi-squared
Secondary
Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12
The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. CR is defined as a CDAI score ≤ 2.8.
Time frame: Week 12
Population: All randomized participants who received at least 1 dose of study drug; last observation carried forward (LOCF) imputation was used for participants with missing data at Week 12 if prior post-baseline data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12 | 4.3 percentage of participants |
| Upadacitinib 3 mg BID | Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12 | 12.2 percentage of participants |
| Upadacitinib 6 mg BID | Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12 | 14.3 percentage of participants |
| Upadacitinib 12 mg BID | Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12 | 6.0 percentage of participants |
| Upadacitinib 18 mg BID | Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12 | 14.3 percentage of participants |
| Upadacitinib 24 mg QD | Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12 | 6.1 percentage of participants |
p-value: 1Chi-squared
p-value: 0.269Chi-squared
p-value: 0.16Chi-squared
p-value: 1Chi-squared
p-value: 0.16Chi-squared
Secondary
Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12
The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA is defined as a CDAI score ≤ 10.
Time frame: Week 12
Population: All randomized participants who received at least 1 dose of study drug; last observation carried forward (LOCF) imputation was used for participants with missing data at Week 12 if prior post-baseline data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12 | 21.3 percentage of participants |
| Upadacitinib 3 mg BID | Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12 | 40.8 percentage of participants |
| Upadacitinib 6 mg BID | Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12 | 40.8 percentage of participants |
| Upadacitinib 12 mg BID | Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12 | 40.0 percentage of participants |
| Upadacitinib 18 mg BID | Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12 | 49.0 percentage of participants |
| Upadacitinib 24 mg QD | Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12 | 36.7 percentage of participants |
p-value: 0.039Chi-squared
p-value: 0.039Chi-squared
p-value: 0.046Chi-squared
p-value: 0.005Chi-squared
p-value: 0.096Chi-squared
Secondary
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale (VAS) from 0 to 100 mm). DAS28(CRP) scores range from 0 to approximately 10 where higher scores indicate more disease activity. LDA is defined as a DAS28(CRP) score \< 3.2.
Time frame: Week 12
Population: All randomized participants who received at least 1 dose of study drug; last observation carried forward (LOCF) imputation was used for participants with missing data at Week 12 if prior post-baseline data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 | 21.3 percentage of participants |
| Upadacitinib 3 mg BID | Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 | 49.0 percentage of participants |
| Upadacitinib 6 mg BID | Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 | 57.1 percentage of participants |
| Upadacitinib 12 mg BID | Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 | 46.0 percentage of participants |
| Upadacitinib 18 mg BID | Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 | 51.0 percentage of participants |
| Upadacitinib 24 mg QD | Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 | 42.9 percentage of participants |
p-value: 0.005Fisher Exact
p-value: <0.001Fisher Exact
p-value: 0.01Fisher Exact
p-value: 0.002Fisher Exact
p-value: 0.024Fisher Exact
Secondary
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 50% improvement in 68-tender joint count; * ≥ 50% improvement in 66-swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician's global assessment of disease activity * Patient's global assessment of disease activity * Patient's assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Population: All randomized participants who received at least 1 dose of study drug; last observation carried forward (LOCF) imputation was used for participants with missing data at Week 12 if prior post-baseline data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 19.6 percentage of participants |
| Upadacitinib 3 mg BID | Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 39.6 percentage of participants |
| Upadacitinib 6 mg BID | Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 49.0 percentage of participants |
| Upadacitinib 12 mg BID | Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 50.0 percentage of participants |
| Upadacitinib 18 mg BID | Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 44.7 percentage of participants |
| Upadacitinib 24 mg QD | Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 43.8 percentage of participants |
p-value: 0.034Chi-squared
p-value: 0.003Chi-squared
p-value: 0.002Chi-squared
p-value: 0.01Chi-squared
p-value: 0.012Chi-squared
Secondary
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Population: All randomized participants who received at least 1 dose of study drug; last observation carried forward (LOCF) imputation was used for participants with missing data at Week 12 if prior post-baseline data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 6.5 percentage of participants |
| Upadacitinib 3 mg BID | Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 23.4 percentage of participants |
| Upadacitinib 6 mg BID | Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 30.6 percentage of participants |
| Upadacitinib 12 mg BID | Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 16.0 percentage of participants |
| Upadacitinib 18 mg BID | Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 27.7 percentage of participants |
| Upadacitinib 24 mg QD | Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 25.0 percentage of participants |
p-value: 0.023Chi-squared
p-value: 0.003Chi-squared
p-value: 0.145Chi-squared
p-value: 0.007Chi-squared
p-value: 0.014Chi-squared
Secondary
Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12
The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale from 0 to 100 mm). DAS28(CRP) scores range from 0 to 10 where higher scores indicate more disease activity. CR is defined as a DAS28(CRP) score \< 2.6.
Time frame: Week 12
Population: All randomized participants who received at least 1 dose of study drug; last observation carried forward (LOCF) imputation was used for participants with missing data at Week 12 if prior post-baseline data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 | 14.9 percentage of participants |
| Upadacitinib 3 mg BID | Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 | 36.7 percentage of participants |
| Upadacitinib 6 mg BID | Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 | 38.8 percentage of participants |
| Upadacitinib 12 mg BID | Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 | 34.0 percentage of participants |
| Upadacitinib 18 mg BID | Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 | 42.9 percentage of participants |
| Upadacitinib 24 mg QD | Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 | 22.4 percentage of participants |
p-value: 0.015Chi-squared
p-value: 0.008Chi-squared
p-value: 0.029Chi-squared
p-value: 0.003Chi-squared
p-value: 0.343Chi-squared